IRIS
MONDELLO, Patrizia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.735
EU - Europa 4.227
AS - Asia 2.312
SA - Sud America 767
Continente sconosciuto - Info sul continente non disponibili 386
AF - Africa 70
OC - Oceania 3
Totale 12.500
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.538
RU - Federazione Russa 1.794
SG - Singapore 999
BR - Brasile 646
CN - Cina 595
IE - Irlanda 532
SE - Svezia 407
IT - Italia 385
PL - Polonia 315
HK - Hong Kong 253
DE - Germania 211
GB - Regno Unito 138
VN - Vietnam 137
FI - Finlandia 125
UA - Ucraina 111
FR - Francia 98
CA - Canada 74
IN - India 62
BD - Bangladesh 56
MX - Messico 33
AR - Argentina 32
NL - Olanda 28
JP - Giappone 26
IQ - Iraq 25
ID - Indonesia 22
CO - Colombia 21
EC - Ecuador 21
BE - Belgio 20
TR - Turchia 18
UZ - Uzbekistan 17
ES - Italia 16
AT - Austria 15
GT - Guatemala 14
JO - Giordania 14
MA - Marocco 13
PY - Paraguay 13
ZA - Sudafrica 13
CW - ???statistics.table.value.countryCode.CW??? 11
NI - Nicaragua 11
PK - Pakistan 11
JM - Giamaica 10
TT - Trinidad e Tobago 10
CR - Costa Rica 9
IL - Israele 9
KE - Kenya 9
PR - Porto Rico 9
PE - Perù 8
VE - Venezuela 8
CL - Cile 7
HN - Honduras 7
MY - Malesia 7
SV - El Salvador 7
TH - Thailandia 7
AZ - Azerbaigian 6
NP - Nepal 6
SC - Seychelles 6
BO - Bolivia 5
CI - Costa d'Avorio 5
CZ - Repubblica Ceca 5
DZ - Algeria 5
GP - Guadalupe 5
TN - Tunisia 5
UY - Uruguay 5
AM - Armenia 4
IR - Iran 4
LB - Libano 4
OM - Oman 4
PA - Panama 4
PH - Filippine 4
SA - Arabia Saudita 4
AL - Albania 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
EE - Estonia 3
EG - Egitto 3
KG - Kirghizistan 3
LT - Lituania 3
PS - Palestinian Territory 3
RO - Romania 3
XK - ???statistics.table.value.countryCode.XK??? 3
AO - Angola 2
AU - Australia 2
BA - Bosnia-Erzegovina 2
ET - Etiopia 2
GE - Georgia 2
KW - Kuwait 2
NG - Nigeria 2
RS - Serbia 2
AE - Emirati Arabi Uniti 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BY - Bielorussia 1
CH - Svizzera 1
CM - Camerun 1
GY - Guiana 1
HR - Croazia 1
IS - Islanda 1
KZ - Kazakistan 1
LI - Liechtenstein 1
Totale 12.116
Salva come PNG Salva come JPEG
Città #
Ashburn 859
Singapore 577
Dublin 531
Moscow 522
Chandler 404
Dallas 330
Warsaw 315
San Jose 284
Hong Kong 252
Nyköping 239
Beijing 189
Council Bluffs 165
Jacksonville 162
Messina 152
Munich 127
Dearborn 98
Los Angeles 96
The Dalles 88
Princeton 84
Medford 73
New York 63
Des Moines 60
Ann Arbor 58
Lauterbourg 54
Lancaster 53
Cambridge 52
Helsinki 51
Houston 50
Santa Clara 46
São Paulo 42
Boardman 36
Wilmington 35
North Bergen 32
Redondo Beach 31
Ho Chi Minh City 29
Hanoi 28
Rome 28
Woodbridge 28
Buffalo 27
Seattle 27
Jinan 25
Rio de Janeiro 25
Dong Ket 24
Tianjin 24
San Mateo 23
Guangzhou 22
Shenyang 22
Chicago 21
Montreal 21
Tokyo 20
Orem 19
Brussels 18
Falls Church 18
Milan 17
Columbus 16
Phoenix 16
Turku 16
Atlanta 15
Baghdad 15
Belo Horizonte 15
Brasília 15
Nuremberg 15
Brooklyn 14
Chennai 14
Jakarta 14
Tashkent 14
Shenzhen 13
Amman 12
Nanchang 12
Nanjing 12
Ningbo 12
Amsterdam 11
Willemstad 11
Boston 10
Frankfurt am Main 10
Guatemala City 10
Managua 10
Shanghai 10
Stockholm 10
Toronto 10
Lappeenranta 9
London 9
Porto Alegre 9
Washington 9
Curitiba 8
Haikou 8
Medellín 8
Mexico City 8
Pune 8
San Francisco 8
Zhengzhou 8
Campinas 7
Dhaka 7
Goiânia 7
Hangzhou 7
Hải Dương 7
Johannesburg 7
Kunming 7
Nairobi 7
Quito 7
Totale 7.163
Salva come PNG Salva come JPEG
Nome #
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. 306
De novo mutation in SLC25A22 gene: expansion of the clinical and electroencephalographic phenotype 302
Bendamustine with Rituximab Is Safe and Effective As FRONT LINE Therapy in Elderly B-CLL Patients. an ITALIAN RETROSPECTIVE MULTICENTER Experience 246
Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma? 231
Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation 229
Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options 224
90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment. 221
Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms 207
Should the Use of Surveillance Imaging in Diffuse Large B-Cell Lymphoma Be Discontinued? 205
90 Y-ibritumomab tiuxetan: A nearly forgotten opportunity 205
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 193
Palmitoylethanolamide Reduces Early Renal Dysfunction and Injury Caused by Experimental Ischemia and Reperfusion in Mice. 188
Emerging markers of cachexia predict survival in cancer patients. 187
Kinase regulation of human MHC class i molecule expression on cancer cells 181
Efficacy of Intravenous Hydrocortisone Treatment in Refractory Neonatal Seizures: A Report on Three Cases 181
90Y-IBRITUMOMAB TIUXETAN CONSOLIDATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVES SURVIVAL OF INTERMEDIATE/HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS NOT RESPONDING ADEQUATELY TO FIRST 179
Biosimilar epoetin α is as effective as originator epoetin-α plus liposomal iron (Sideral®), vitamin B12 and folates in patients with refractory anemia: A retrospective real-life approach 179
Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression. 174
Thyroid hormone autoantibodies: Are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments? 174
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience 173
An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules. 170
Congenital heart disease in down syndrome 170
Complications of trauma patients admitted to the ICU in level i academic trauma centers in the United States 168
90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward? 168
Relapsed or refractory extranodal DLBCL treated with lenalidomide: A single center study 161
STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma 161
Thyroid function, autoimmunity and nodules in hematological malignancies 157
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE TREATMENT IN CLL PATIENTS 152
Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma 151
The heart in Anderson-Fabry disease 150
BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors 149
Protective effect of apocynin, a NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rats: a comparison with n-acetylcysteine. 143
Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial. 143
Glutamine-supplemented total parenteral nutrition improves immunological status in anorectic patients 141
A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies 140
ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study 135
Characterization of immune exhaustion and suppression in the tumor microenvironment of splenic marginal zone lymphoma 134
Glutamine contributes to ameliorate inflammation after renal ischemia/reperfusion injury in rats 131
Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy? 128
Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease. 126
Glutamine treatment attenuates the development of organ injury induced by zymosan administration in mice 125
Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent 125
Glutamine treatment attenuates the development of ischaemia/reperfusion injury of the gut. 124
Treatment of Aggressive B Cell Lymphomas: Updates in 2019 124
Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP 120
Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature. 118
Thalidomide suppresses sclerosing encapsulating peritonitis in a rat experimental model 117
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib 117
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study 115
Circulating Mitotic Figures In A Patient With Dual Infection By Epstein-Barr Virus And Cytomegalovirus. 112
Effects of Apocynin, A Nadph-oxidase Inhibitor, In Contrast-induced Nephropathy 112
null 111
null 107
null 105
null 105
Insights into the tumor microenvironment of B cell lymphoma 100
Primary central nervous system lymphoma: Novel precision therapies 100
PHASE II TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER TREATMENT WITH LENALIDOMIDE AND BORTEZOMIB 99
null 99
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma 98
null 96
null 95
Emerging drugs for diffuse large B-cell lymphoma. 95
Silencing GNAS enhances HDAC3i efficacy in CREBBP wild type B cell lymphoma 94
Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study 93
null 93
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study 92
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse 91
null 90
MicroRNA and long non-coding RNA analysis in IgM monoclonal gammopathies reveals epigenetic influence on cellular functions and oncogenesis 89
Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma 83
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma. 81
null 81
null 79
Simplified risk stratification model for patients with Waldenström macroglobulinemia 78
null 75
PHOENIX rises: Genomic-based therapies for diffuse large B cell lymphoma 75
Pim kinases in hematological malignancies: where are we now and where are we going? 73
null 72
Biosimilar Erythropoietin Alpha Is Effective As Originator Erythropoietin Alpha Plus Liposomial Iron and B12 and Folates in Patients with Refractory Anemia: A Retrospective Real-Life Approach 72
Questionable Validity of Cardiac Risk Score on the Basis of the NSABP B-31 Model 69
null 67
null 66
null 64
Reshaping the therapeutic landscape of chronic lymphocytic leukaemia in the era of targeted therapy 61
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL 50
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. 49
R-CHOP versus R-COMP: are they really equally effective? 47
null 46
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts 44
Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies 42
Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. 42
null 41
Multi-omics analysis in IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation 37
Radiotherapy for stage I/II follicular lymphoma (FL): is it time for a re-appraisal? 37
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma 36
null 35
Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation 35
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma 33
null 33
Totale 12.027
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.779
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.779
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022474 0 0 0 0 30 19 20 19 8 104 66 208
2022/20231.490 136 128 85 119 91 141 14 80 628 18 37 13
2023/2024331 23 53 22 26 20 57 18 33 5 23 20 31
2024/20251.865 14 19 34 118 103 82 118 418 414 132 142 271
2025/20265.222 216 333 376 423 511 969 711 572 590 279 95 147
2026/20271.274 192 242 274 454 112 0 0 0 0 0 0 0
Totale 12.500